NeoGenomics stock trades up as streamlined RaDaR ST workflow targets pharma partners

Traders Union
All News
Companies
NeoGenomics up 0.49% today at $10.17

Highlights

NEO maintains a bullish bias across short-, medium-, and long-term technical indicators, trading above key moving averages and support levels.
Momentum indicators suggest strong but potentially overbought conditions, with some divergence as MACD and ADX signal buying while overbought warnings appear.
NEO is expected to trade sideways within the $9.70–$10.50 range; a move above $10.68 signals bullish continuation, while a drop below $9.67 increases downside risk.

Bullish trends hold as price remains above key support levels

NEO is trading at $10.17, which is above its MA-20 ($9.11), MA-50 ($8.55), and MA-200 ($9.75), indicating short-, medium-, and long-term bullish trends are confirmed. The Ichimoku Kijun on D1 sits at $9.41, providing immediate support below the current price. Near-term support levels are seen at the Ichimoku Kijun ($9.41) and MA-200 ($9.75), while key support lies at MA-100 ($9.67). For resistance, near-term levels appear at MA-5 ($10.17) and key resistance is marked by HMA ($10.68).

Mixed overbought signals as recent gains meet weekly pullback

Momentum is broadly positive on D1 as both MACD and ADX favor buying, while RSI is at 65.32 and in the upper neutral zone. CCI and BBP both flag overbought conditions and strong buyer dominance, but Stoch RSI is at 71.04 and neutral. The Awesome Oscillator aligns with the bullish momentum. NEO has fallen $0.35 (3.61%) from last week’s close of $10.52. It is currently in the upper part of its recent weekly range. Weekly volatility stands at 13.06%. Recent moves reflect a steady decline from last week’s highs with some recovery, while conflicting overbought signs suggest caution if momentum fades.

Sideways bias dominates as bullish and bearish risks evenly balanced

For the upcoming week, a realistic range is projected between $9.70 and $10.50, keeping within 8% of the current price and consistent with typical volatility. With RSI-W1 and MA-50-W1 showing buy signals and ADX-W1 neutral but MACD-W1 signaling strong sell, the chance of a price increase is moderate, estimated at 50%. The probability of a decline is equally likely. The baseline scenario is continued sideways movement in the $9.70–$10.50 band. A bullish breakout would require clearance above $10.68, opening the way for further gains. A bearish scenario would see a drop below $9.67, exposing NEO to further selling pressure toward support. This forecast range remains well above the 52-week low ($4.72) but below the 52-week high ($13.74), placing NEO in the upper third of its annual range.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that NeoGenomics showcased its innovations in precision oncology at the USCAP 115th Annual Meeting to engage with leading experts in cancer diagnostics. As the company's developments in pathology continue to gain attention, investors should watch for potential momentum shifts that could influence the stock's prevailing scenario in the near term.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.